RxDoctor Payments Data

Mary Marshall

Gastroenterology · Mobile, ALNPI 1336502822

Payments from drug & device makers

$3,953in general payments, 2019–2025

Across 162 payments — averaging $24.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Olympus Corporation Of The Americas$888
  • Takeda Pharmaceuticals U.S.A., Inc.$638
  • Ardelyx, Inc.$232
  • Braintree Laboratories, Inc.$147
  • Johnson & Johnson$142
  • plus $763 from 18 others

What the payments were for

  • Travel & lodging$72718%
  • Food & beverage$3,12779%
  • Education$993%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,953 in reported general payments places this provider in the 45th percentile of 225 gastroenterology providers in Alabama.

See all gastroenterology providers in Alabama

Medicare billing

Part B allowed, 2024
$41,426
Medicare patients
192
Services billed
400

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntyvioVedolizumab16$138,665
LinzessLinaclotide52$31,078
TrulancePlecanatide41$22,784
MotegrityPrucalopride Succinate20$10,250
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates70$4,569
Colesevelam Hcl11$2,914
Pantoprazole Sodium111$1,642
Famotidine98$1,349
Omeprazole108$1,257
Colestipol Hcl13$1,222
Dicyclomine Hcl27$203
Lactulose11$103
Promethazine Hcl20$93

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Takeda Pharmaceuticals U.S.A., Inc.Entyvio, Motegrity$638$148,91636 claims
AbbVieLinzess$1,143$31,07852 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance$53$22,78441 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 225 gastroenterology providers in Alabama.

Other gastroenterology in Mobile

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →